Met Life Investment Management, LLC Biocryst Pharmaceuticals Inc Transaction History
Met Life Investment Management, LLC
- $16.5 Billion
- Q2 2025
A detailed history of Met Life Investment Management, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 124,277 shares of BCRX stock, worth $910,950. This represents 0.01% of its overall portfolio holdings.
Number of Shares
124,277
Previous 121,918
1.93%
Holding current value
$910,950
Previous $914,000
21.77%
% of portfolio
0.01%
Previous 0.01%
Shares
45 transactions
Others Institutions Holding BCRX
# of Institutions
316Shares Held
202MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$151 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$146 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$62.3 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$62 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$41.9 Million0.09% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.36B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...